[CLSTR]
< Back to situation

[REVISION HISTORY]

US biotech Q2 earnings reports

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-05 01:04 UTC → 2026-08-05 17:42 UTC · added removed

In late July 2026, 2026 Biogen announced its second‑quarter results, showing posted a modest 3% year‑over‑year revenue increase rise to $2.7 billion and modest earnings per share. Sales of billion, driven by its multiple‑sclerosis drugs and newer products such as Skyclarys and Leqembi contributed to the growth, while Australian biotech peers also reported solid figures. Leqembi. A week later, later Amgen reported a stronger Q2 performance, with Q2 revenue up 9% to $10.1 billion and earnings per share surpassing expectations. The company highlighted robust sales of its cholesterol drug Repatha and bone‑health product Evenity, as well as significant gains in rare‑disease medicines. Amgen also raised its full‑year outlook, underscoring a broader trend of healthy earnings among major US biotech firms in the second quarter of 2026. On 4 August 2026, beating expectations, while Gilead Sciences posted second‑quarter announced an 8% increase in product sales of to $7.8 billion, an 8% year‑over‑year rise driven led by double‑digit growth in its HIV portfolio. HIV On 4 August 2026 Amgen confirmed its 9% sales climbed 12%, led by Descovy, which jumped 48% to $967 million, growth, posted adjusted earnings of $6.29 per share, and Biktarvy, up 7% raised its full‑year earnings outlook to $3.8 $22.30‑$23.50 per share on revenue of $38.2‑$39.4 billion. The company also reported strong results for disclosed the discontinuation of its liver‑disease drug Livdelzi and cancer obesity drug Trodelvy. Although candidate AMG 513. Gilead recorded an reiterated its adjusted loss of $6.75 per share—better share, better than the $7.24 expected—it narrowed its 2026 adjusted‑loss outlook to $0.30‑$0.65 per share forecasts, and raised the lower end of its full‑year revenue target to $30.1‑$30.4 billion. COVID‑19 antiviral Veklury sales fell sharply, while the firm highlighted growth continued strength in HIV, liver‑disease, and oncology segments. Other biotech peers reported mixed results: Geron recorded a Q2 loss of $16.7 million on $57.5 million revenue, driven by its HIV prevention oncology drug Yeztugo and continued expansion RYTELO; Rigel Pharmaceuticals earned $0.88 per share, beating expectations, with $67 million in oncology commercial revenue; Precigen posted a modest EPS beat of $0.05 on $55 million revenue; and liver‑disease segments. TG Therapeutics saw BRIUMVI sales jump 64% to $227.7 million. The series of reports underscores a broadly healthy earnings environment for major U.S. biotech firms in the second quarter of 2026.

Versions

  1. 2026-08-05 17:42 UTC US biotech Q2 earnings reports
  2. 2026-08-05 01:04 UTC US biotech Q2 earnings reports
  3. 2026-08-04 20:43 UTC US biotech Q2 earnings reports

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.